← Back to Clinical Trials
Recruiting NCT06329739

NCT06329739 Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06329739
Status Recruiting
Phase
Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Condition Parkinson Disease
Study Type OBSERVATIONAL
Enrollment 68 participants
Start Date 2021-12-14
Primary Completion 2031-12-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Clinical examinations and clinical scales administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 68 participants in total. It began in 2021-12-14 with a primary completion date of 2031-12-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD. The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients. Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years. Researchers will compare data collected from patients with genetic mutation versus patients without mutation.

Eligibility Criteria

Inclusion Criteria: * diagnosed with Parkinson's Disease (PD) * in use of dopaminergic medication (L-Dopa and/or dopamine agonists) * genetic testing for mendelian forms of PD * able to provide informed consent to participate in the study Exclusion Criteria: * Patients underwent Deep Brain Stimulation (DBS) treatment

Contact & Investigator

Central Contact

Francesca Mameli, Dr

✉ francesca.mameli@policlinico.mi.it

📞 0255033621

Principal Investigator

Francesca Mameli, Dr

PRINCIPAL INVESTIGATOR

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Frequently Asked Questions

Who can join the NCT06329739 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06329739 currently recruiting?

Yes, NCT06329739 is actively recruiting participants. Contact the research team at francesca.mameli@policlinico.mi.it for enrollment information.

Where is the NCT06329739 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06329739 clinical trial?

NCT06329739 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The principal investigator is Francesca Mameli, Dr at Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 68 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology